Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

bioAffinity Technologies (BIAF) EBT: 2022-2025

Historic EBT for bioAffinity Technologies (BIAF) over the last 4 years, with Sep 2025 value amounting to -$5.0 million.

  • bioAffinity Technologies' EBT fell 152.61% to -$5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.7 million, marking a year-over-year decrease of 74.31%. This contributed to the annual value of -$9.0 million for FY2024, which is 14.05% down from last year.
  • Latest data reveals that bioAffinity Technologies reported EBT of -$5.0 million as of Q3 2025, which was down 25.20% from -$4.0 million recorded in Q2 2025.
  • In the past 5 years, bioAffinity Technologies' EBT registered a high of -$88,052 during Q2 2022, and its lowest value of -$5.0 million during Q3 2025.
  • In the last 3 years, bioAffinity Technologies' EBT had a median value of -$2.3 million in 2023 and averaged -$2.6 million.
  • Over the last 5 years, bioAffinity Technologies' EBT had its largest YoY gain of 53.48% in 2023, and its largest YoY loss of 1,871.09% in 2023.
  • bioAffinity Technologies' EBT (Quarterly) stood at -$1.7 million in 2022, then slumped by 41.58% to -$2.4 million in 2023, then dropped by 25.14% to -$3.0 million in 2024, then plummeted by 152.61% to -$5.0 million in 2025.
  • Its EBT was -$5.0 million in Q3 2025, compared to -$4.0 million in Q2 2025 and -$2.7 million in Q1 2025.